News

LakeShore Biopharma Announces US$15 Million Private Placement Financing

BEIJING , July 8, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) (the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has entered into a share and warrant purchase agreement (the "Purchase Agreement") with an institutional investor for the issuance and sale of 16,987,542 ordinary shares of the Company, par value US$0.0002 per share, at US$0.883 per share, and 16,987,542 warrants, each entitling the institutional investor to purchase one ordinary share at an exercise price of US$1.079 at any time and from time to time during a 36-month period, in a private placement of US$15 million exempt from registration pursuant to Regulation S under the Securities Act of 1933, as amended. The closing of the private placement is expected to take place as soon as possible upon agreement by the parties to the Purchase Agreement, subject to customary conditions precedent stipulated thereunder.

07/08/2025

LSB Industries, Inc. to Participate in UBS Energy Transition and Decarbonization Conference on Wednesday, May 14th

OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB” or the “Company”), today announced that its Vice President of Clean Energy, Jakob Krummenacher, will participate in the UBS Energy Transition and Decarbonization Conference in New York City on Wednesday, May 14th. Mr. Krummenacher will be available for one-on-one meetings all day at the conference. Additionally, Mr. Krummenacher will be participating in a panel discussion, “Scaling Carbon Capture Solutions Across Industry”.

05/09/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is 331 (LSB) a buy, sell, or hold?

331 (LSB) can sell. Click on Rating Page for detail.

What is 331's stock price?

The price of 331 (LSB) is 1.09 and it was updated on 2025-07-11 13:00:27.

Is 331 (LSB) overvalued or undervalued?

Currently 331 (LSB) is in undervalued.

News

From:

To:

News
LSB Industries, Inc. Reports Operating Results for the 2025 First Quarter OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB,” “we,” “us,” “our,” or the “Company”) today announced results for the first quarter ended March 31, 2025. First Quarter 2025 Results and Recent Highlights Net sales of $143.4 million compared to $138.2 million in the first quarter of 2024 Net loss of $1.6 million compared to a net income of $5.6 million in the first quarter of 2024 Diluted EPS of $(0.02) compared to $0.08 for the first quarter of 2024 Adjusted EBITDA(1) of. Tue, Apr. 29, 2025
LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell) Revolutionizing Vaccination Safety with Needle-Free Reconstitution Technology BEIJING , April 23, 2025 /PRNewswire/ -- On April 18, 2025, LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company") successfully held the 2025 CSO ("Contract Sales Organization") Annual Meeting and the launch meeting of YSJA™ rabies vaccine (Vero cell) novel packaging solution (liquid drug transfer device) in Changsha, Hunan Province. Wed, Apr. 23, 2025
LSB Industries, Inc. Schedules 2025 First Quarter Results Release for Tuesday, April 29th and Conference Call for Wednesday, April 30th OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB”) (NYSE: LXU), today announced that it will release its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 after the close of the stock market. LSB's management will host a conference call on Wednesday, April 30, 2025 at 10:00 am ET / 9:00 am CT to discuss these results. Participating in the call will be Chairman, President & Chief Executive Officer, Mark Behrman, Executive Vice President & C. Tue, Apr. 15, 2025
LSB Industries, Inc. Appoints Riccardo Bertocco as an Independent Member of the Board of Directors OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB” or the “Company”), today announced that it has appointed Riccardo Bertocco as an independent member of the Board of Directors (“the Board”) of the Company effective April 9, 2025. Mr. Bertocco will stand for direct election by shareholders for the first time at the annual meeting of stockholders on May 15, 2025 (the “2025 Annual Meeting”). Mr. Bertocco has worked extensively in management consulting for more than 25 years,. Thu, Apr. 10, 2025
LSB Industries, Inc. Reports Operating Results for the 2024 Fourth Quarter and Full Year and Provides Product Sales Volume Outlook for 2025 OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB,” “we,” “us,” “our,” or the “Company”) today announced results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Results and Recent Highlights Net sales of $134.9 million compared to $132.6 million in the fourth quarter of 2023 Net loss of $9.1 million compared to a net loss of $5.3 million in the fourth quarter of 2023; the fourth quarter 2024 net loss included approximately $17.1 million of. Wed, Feb. 26, 2025

Transcripts

Transcipts Data
331 (LSB) on Q3 2024 Results - Earnings Call Transcript SA Transcripts Fri, Apr. 19, 2024

SEC Filings

SEC Filings
331 (LSB) - 6-K - Current report SEC Filings 07/08/2025
331 (LSB) - 6-K - Current report SEC Filings 05/12/2025
331 (LSB) - 6-K - Current report SEC Filings 05/06/2025
331 (LSB) - 6-K - Current report SEC Filings 03/25/2025
331 (LSB) - S-8 POS SEC Filings 03/14/2025
331 (LSB) - 6-K - Current report SEC Filings 03/12/2025
331 (LSB) - 6-K - Current report SEC Filings 12/19/2024
331 (LSB) - 6-K - Current report SEC Filings 12/12/2024
331 (LSB) - 6-K - Current report SEC Filings 11/12/2024
331 (LSB) - 6-K - Current report SEC Filings 11/07/2024
331 (LSB) - 6-K - Current report SEC Filings 11/01/2024
331 (LSB) - 6-K - Current report SEC Filings 10/29/2024
331 (LSB) - 6-K - Current report SEC Filings 10/25/2024
331 (LSB) - 6-K - Current report SEC Filings 10/08/2024
331 (LSB) - 6-K - Current report SEC Filings 09/27/2024
331 (LSB) - 6-K/A - Current report SEC Filings 09/10/2024
331 (LSB) - 6-K - Current report SEC Filings 09/10/2024
331 (LSB) - 6-K - Current report SEC Filings 09/04/2024
331 (LSB) - 6-K - Current report SEC Filings 08/15/2024
331 (LSB) - 20-F SEC Filings 08/15/2024
331 (LSB) - NT 20-F SEC Filings 07/31/2024
331 (LSB) - 6-K - Current report SEC Filings 07/05/2024
331 (LSB) - 6-K - Current report SEC Filings 06/18/2024
331 (LSB) - 6-K - Current report SEC Filings 06/10/2024
331 (LSB) - 6-K - Current report SEC Filings 05/24/2024
331 (LSB) - 6-K - Current report SEC Filings 05/21/2024
331 (LSB) - S-8 SEC Filings 05/20/2024
331 (LSB) - 424B3 SEC Filings 05/08/2024
331 (LSB) - 6-K - Current report SEC Filings 05/07/2024
331 (LSB) - 6-K - Current report SEC Filings 04/29/2024
331 (LSB) - 6-K - Current report SEC Filings 04/19/2024
331 (LSB) - 6-K - Current report SEC Filings 04/18/2024
331 (LSB) - 6-K - Current report SEC Filings 04/09/2024
331 (LSB) - 6-K - Current report SEC Filings 04/03/2024
331 (LSB) - 6-K - Current report SEC Filings 03/05/2024
331 (LSB) - 6-K - Current report SEC Filings 02/23/2024
331 (LSB) - 6-K - Current report SEC Filings 02/22/2024
331 (LSB) - 6-K - Current report SEC Filings 02/20/2024
331 (LSB) - SC 13G/A SEC Filings 02/16/2024
331 (LSB) - SC 13G SEC Filings 02/15/2024
331 (LSB) - SC 13D SEC Filings 02/14/2024
331 (LSB) - 6-K - Current report SEC Filings 02/14/2024
331 (LSB) - 6-K - Current report SEC Filings 02/09/2024
331 (LSB) - 6-K - Current report SEC Filings 01/26/2024
331 (LSB) - EFFECT SEC Filings 01/25/2024
331 (LSB) - POS AM SEC Filings 01/23/2024
331 (LSB) - 6-K - Current report SEC Filings 01/22/2024
331 (LSB) - 6-K - Current report SEC Filings 01/08/2024
331 (LSB) - 6-K - Current report SEC Filings 12/28/2023
331 (LSB) - 6-K - Current report SEC Filings 12/20/2023
331 (LSB) - 6-K - Current report SEC Filings 12/12/2023
331 (LSB) - 6-K - Current report SEC Filings 11/14/2023
331 (LSB) - 6-K - Current report SEC Filings 10/31/2023
331 (LSB) - 424B3 SEC Filings 10/31/2023
331 (LSB) - 6-K - Current report SEC Filings 10/26/2023
331 (LSB) - 6-K - Current report SEC Filings 09/26/2023
331 (LSB) - 424B3 SEC Filings 09/26/2023
331 (LSB) - 424B3 SEC Filings 09/25/2023
331 (LSB) - 6-K - Current report SEC Filings 08/25/2023
331 (LSB) - 6-K - Current report SEC Filings 08/16/2023
331 (LSB) - 424B3 SEC Filings 08/15/2023
331 (LSB) - EFFECT SEC Filings 08/10/2023
331 (LSB) - POS AM SEC Filings 08/08/2023
331 (LSB) - 20-F SEC Filings 07/26/2023
331 (LSB) - S-8 SEC Filings 07/07/2023
331 (LSB) - EFFECT SEC Filings 06/05/2023
331 (LSB) - 424B3 SEC Filings 06/05/2023
331 (LSB) - 6-K - Current report SEC Filings 06/01/2023
331 (LSB) - CORRESP SEC Filings 05/31/2023
331 (LSB) - 6-K - Current report SEC Filings 05/18/2023
331 (LSB) - 6-K - Current report SEC Filings 05/16/2023
331 (LSB) - F-1/A SEC Filings 05/12/2023
331 (LSB) - CORRESP SEC Filings 05/12/2023
331 (LSB) - UPLOAD SEC Filings 04/26/2023
331 (LSB) - 6-K - Current report SEC Filings 04/18/2023
331 (LSB) - F-1 SEC Filings 04/12/2023
331 (LSB) - 6-K - Current report SEC Filings 03/27/2023
331 (LSB) - 6-K - Current report SEC Filings 03/17/2023
331 (LSB) - CERT SEC Filings 03/16/2023
331 (LSB) - 425 SEC Filings 03/14/2023
331 (LSB) - 425 SEC Filings 02/21/2023
331 (LSB) - 424B3 SEC Filings 02/21/2023
331 (LSB) - 425 SEC Filings 02/08/2023
331 (LSB) - 424B3 SEC Filings 02/08/2023
331 (LSB) - EFFECT SEC Filings 02/07/2023
331 (LSB) - F-4/A SEC Filings 02/03/2023
331 (LSB) - CORRESP SEC Filings 02/02/2023
331 (LSB) - F-4/A SEC Filings 01/25/2023
331 (LSB) - CORRESP SEC Filings 01/25/2023
331 (LSB) - 8-A12B SEC Filings 01/20/2023
331 (LSB) - UPLOAD SEC Filings 01/19/2023
331 (LSB) - F-4/A SEC Filings 01/13/2023
331 (LSB) - CORRESP SEC Filings 01/13/2023
331 (LSB) - UPLOAD SEC Filings 01/06/2023
331 (LSB) - F-4 SEC Filings 12/28/2022
331 (LSB) - CORRESP SEC Filings 12/28/2022
331 (LSB) - UPLOAD SEC Filings 12/16/2022
331 (LSB) - DRSLTR SEC Filings 12/07/2022
331 (LSB) - DRS/A SEC Filings 12/07/2022
331 (LSB) - UPLOAD SEC Filings 11/23/2022
331 (LSB) - DRSLTR SEC Filings 11/14/2022
331 (LSB) - DRS/A SEC Filings 11/14/2022
331 (LSB) - UPLOAD SEC Filings 10/31/2022
331 (LSB) - DRSLTR SEC Filings 10/03/2022
331 (LSB) - DRS SEC Filings 10/03/2022
331 (LSB) - 425 SEC Filings 09/29/2022

Press Releases

StockPrice Release
Lakeshore biopharma announces us$15 million private placement financing 07/08/2025
Lsb industries, inc. to participate in ubs energy transition and decarbonization conference on wednesday, may 14th 05/09/2025
Lsb industries, inc. reports operating results for the 2025 first quarter 04/29/2025
Lakeshore biopharma announces the official launch of a novel packaging solution for ysja™ rabies vaccine (vero cell) 04/23/2025
Lsb industries, inc. schedules 2025 first quarter results release for tuesday, april 29th and conference call for wednesday, april 30th 04/15/2025
Lsb industries, inc. appoints riccardo bertocco as an independent member of the board of directors 04/10/2025
Lsb industries, inc. reports operating results for the 2024 fourth quarter and full year and provides product sales volume outlook for 2025 02/26/2025
Lsb industries, inc. schedules 2024 fourth quarter and full year financial results release for wednesday, february 26th and conference call for thursday, february 27th 02/06/2025
Lakeshore biopharma reports unaudited financial results for the first half of fiscal year 2025 and updates full-year guidance 12/19/2024
Lakeshore biopharma provides update on ongoing criminal investigation involving former chairman in china 12/12/2024
Lsb industries announces publication of 2023 sustainability report 12/03/2024
Lsb industries, inc. appoints john chandler as an independent member of the board of directors 11/11/2024
Lsb industries, inc. reports operating results for the 2024 third quarter 10/29/2024
Lakeshore biopharma regains compliance with nasdaq minimum bid price requirement 10/29/2024
Lakeshore biopharma granted phase iii clinical trial approval to explore simplified regimens for ysja rabies vaccine 10/25/2024
Lsb industries, inc. schedules 2024 third quarter financial results release for tuesday, october 29th and conference call for wednesday, october 30th 10/10/2024
Lakeshore biopharma provides fiscal half year 2025 financial guidance and reaffirms fiscal year 2025 financial guidance 10/08/2024
Lakeshore biopharma announces results of extraordinary general meeting on share consolidation 09/27/2024
Lakeshore biopharma to hold an extraordinary general meeting of shareholders on september 27, 2024 09/10/2024
Lakeshore biopharma announces leadership transitions 09/04/2024
Lakeshore biopharma announces financial results for fiscal year 2024 08/15/2024
Lakeshore biopharma to hold an extraordinary general meeting on july 25, 2024, pursuant to shareholders' requisition 07/05/2024

More Headlines

News
LSB Industries, Inc. Schedules 2024 Fourth Quarter and Full Year Financial Results Release for Wednesday, February 26th and Conference Call for Thursday, February 27th OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB”) (NYSE: LXU), today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, February 26, 2025 after the close of the stock market. LSB's management will host a conference call on Thursday, February 27, 2025 at 10:00 am ET / 9:00 am CT to discuss these results. Participating in the call will be Chairman, President & Chief Executive Officer, Mark Behrman, Executi. 02/06/2025
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoY Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY Gross margin increased to 82.6% from 80.9% in the same period of FY2024 Total operating expenses decreased to RMB 276.4 million, down 31.6% YoY Recorded net income of RMB 20.6 million, and adjusted net income[1] (Non-GAAP) of RMB 30.4 million, compared to net loss and adjusted net loss[1] (Non-GAAP) of RMB 174.5 million in the same period of FY2024 BEIJING , Dec. 19, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its financial results for the first six months ended September 30, 2024 ("FY2025H1"). 12/19/2024
LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China BEIJING, Dec. 12, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a leading global biopharmaceutical company focused on the innovation and production of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the Shenyang Municipal Public Security Bureau in China (the “Bureau”) has initiated criminal investigations into actions taken by former chairman of the board of directors Yi Zhang (“Former Chairman”). 12/12/2024
LSB Industries Announces Publication of 2023 Sustainability Report OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB” or “the Company”), (NYSE: LXU) today announced the publication of its 2023 Sustainability Report, highlighting the Company's progress in advancing its sustainability efforts. LSB remains focused on its vision of being a leader in the clean energy transition through the production and delivery of low carbon products to multiple end markets. Additionally, the Company prioritizes its involvement in activities that support the long-term su. 12/03/2024
LSB Industries, Inc. Appoints John Chandler as an Independent Member of the Board of Directors OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB” or “the Company”), (NYSE: LXU) today announced that it has appointed John Chandler as an independent member of the Board of Directors (the “Board”) effective November 7, 2024. Mr. Chandler was also appointed to the audit committee of the Board. Mr. Chandler has more than 30 years of experience in the energy industry, predominantly in financial leadership and business development roles. Most recently, he served as Chief Financial Office. 11/11/2024
LSB Industries, Inc. Reports Operating Results for the 2024 Third Quarter OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB” or the “Company”) today announced results for the third quarter ended September 30, 2024. Third Quarter 2024 Results and Recent Highlights Net sales of $109.2 million compared to $114.3 million in the third quarter of 2023 Net loss of $25.4 million compared to a net loss of $7.7 million in the third quarter of 2023; the third quarter 2024 net loss included approximately $16.3 million of turnaround costs and approximately $5. 10/29/2024
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement GAITHERSBURG, Md., Oct. 29, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has received a written notice (the "Compliance Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated October 21, 2024, informing the Company that it has regained compliance with the minimum bid price requirement set forth under the Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). 10/29/2024
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine GAITHERSBURG, Md. , Oct. 25, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has been granted approval for a Phase III clinical trial (the "Trial") by the National Medical Products Administration (NMPA) in China to explore the immunogenicity and safety of a simplified four-dose regimen for its YSJA rabies vaccine which is the first generation of the Company's rabies vaccine and has sold more than 100M doses since its market approval. 10/25/2024
LSB Industries, Inc. Schedules 2024 Third Quarter Financial Results Release for Tuesday, October 29th and Conference Call for Wednesday, October 30th OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB”), (NYSE: LXU), today announced that it will release its financial results for the third quarter ended September 30, 2024 on Tuesday, October 29, 2024 after the close of the stock market. LSB's management will host a conference call on Wednesday, October 30, 2024 at 10:00 am ET / 9:00 am CT to discuss these results. Participating in the call will be Chairman, President & Chief Executive Officer, Mark Behrman, Executive Vice Presiden. 10/10/2024
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance GAITHERSBURG, Md. , Oct. 8, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it is providing financial guidance for the half year of its fiscal year of 2025 and reaffirming its financial guidance for the full year of its fiscal year 2025 ending on March 31, 2025 ("Fiscal Year 2025"), underlining the Company's strong execution and positive business momentum. 10/08/2024
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation GAITHERSBURG, Md. , Sept. 27, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the results of its extraordinary general meeting (the "EGM") held on September 27, 2024 (Beijing Time) virtually via a Zoom video conference call. 09/27/2024
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024 GAITHERSBURG, Md. , Sept. 10, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it will hold an extraordinary general meeting of shareholders (the "EGM") at 10:00 a.m. 09/10/2024
LakeShore Biopharma Announces Leadership Transitions GAITHERSBURG, Md. , Sept. 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. 09/04/2024
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 Gross margin increased to 79.5%; product pipeline continues to advance Company anticipates double-digit year-over-year revenue growth and bottom line breakeven for Fiscal Year 2025 GAITHERSBURG, Md. , Aug. 15, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. 08/15/2024
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition GAITHERSBURG, Md. , July 5, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the Company received a shareholders' requisition dated June 14, 2024, issued by certain shareholders of the Company holding shares which carry in aggregate not less than 10% of all votes attaching to all issued and outstanding shares of the Company, including Yi Zhang, All Brilliance Investments Limited, Apex Pride Global Limited, Hopeful World Company Limited, and Acton Town International Limited (together, the "Requisitioning Shareholders"), requesting the directors of the Company to convene an extraordinary general meeting (the "EGM") of the Company (the "Requisition") to provide explanations to the shareholders of the Company on matters as described below: The circumstances leading to the filing of the United States Securities and Exchange Commission Form 6-K Report, filed on June 10, 2024 (the "SEC Report"), including the reasons for the resignation of each of the former directors specified in the SEC Report. 07/05/2024

Unlock

LSB Ratings Summary

LSB Quant Ranking

Is 331 (LSB) a buy, sell, or hold?

What is 331's stock price?

Is 331 (LSB) overvalued or undervalued?

LSB Industries, Inc. Schedules 2024 Fourth Quarter and Full Year Financial Results Release for Wednesday, February 26th and Conference Call for Thursday, February 27th

LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance

LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China

LSB Industries Announces Publication of 2023 Sustainability Report

LSB Industries, Inc. Appoints John Chandler as an Independent Member of the Board of Directors

LSB Industries, Inc. Reports Operating Results for the 2024 Third Quarter

LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine

LSB Industries, Inc. Schedules 2024 Third Quarter Financial Results Release for Tuesday, October 29th and Conference Call for Wednesday, October 30th

LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance

LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation